Compare Kroger Co (KR) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Mesoblast Limited — how do they compare? Kroger Co trades at $57.26 (market cap $35.75B), while Mesoblast Limited trades at $16.36 (market cap $2.17B). The key difference: Kroger Co is far larger — about 16.5× Mesoblast Limited's market cap, and Kroger Co pays a 2.47% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| KR | MESO | |
|---|---|---|
Market Cap | $35.75B | $2.17B |
Sector | Consumer Staples | Technology |
52-Week High | $75.60 | $20.96 |
52-Week Low | $55.53 | $12.88 |
Enterprise Value | $55.85B | $2.17B |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $58.39, down 0.73% on the day, with a bearish technical signal and mixed earnings history. The company maintains stable revenue near $147 billion (2025) and recently announced a $1.65 billion acquisition of Giant Eagle (Reuters, July 1, 2026). Cash flow from operations remains strong at $5.79 billion, though net income margin is thin at 0.71%.
Outlook: KR offers value with low P/S (0.25) and dividend yield, but faces margin pressure and integration risks from acquisitions. Analyst consensus is bullish with a $68.63 price target, though technical weakness and competitive threats warrant caution for near-term volatility.
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
